Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma Journal Article
| Authors: | McCaffrey, J. A.; Hilton, S.; Mazumdar, M.; Sadan, S.; Kelly, W. K.; Scher, H. I.; Bajorin, D. F. |
| Article Title: | Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma |
| Abstract: | Purpose: A phase II trial of docetaxel was conducted to assess its efficacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to respond to prior cisplatin-based therapy. Patients and Methods: Thirty assessable patients who had failed to respond to or relapsed after one prior cisplatin-containing regimen were treated with docetaxel 100 mg/m2 over 1 hour, every 21 days. All patients were premedicated with dexamethasone and diphenhydramine to reduce allergic reactions. Reductions of subsequent doses were made for severe hematologic toxicity. Prophylactic hematopoietic growth factors were not used. Results: Four of 30 patients (13.3%; 95% confidence interval [CI], 3.8% to 30.7%) demonstrated a partial response (PR), with durations of response ranging from 3 to 8 months. The estimated median survival duration for all patients is 9 months (95% CI, 6 to 12 months) with a median follow-up time of 14 months (range, 1 to 27). Hematologic toxicity included anemia, thrombocytopenia, neutropenia, and febrile neutropenia. Nonhematologic toxicity included alopecia and mucositis. Fluid retention was not observed and cutaneous toxicity was mild and infrequent. Dose reductions were necessary for adverse events in 18 patients (60%). Conclusion: Docetaxel is an active single agent in previously treated patients with TCC of the urothelial tract. Therapy was well tolerated in this patient population but myelosuppression was frequent. Further study in previously untreated patients, both alone and in combination, is warranted. |
| Keywords: | adult; cancer survival; clinical article; aged; middle aged; survival analysis; clinical trial; advanced cancer; drug efficacy; skin toxicity; paclitaxel; neurotoxicity; metastasis; phase 2 clinical trial; blood toxicity; gastrointestinal symptom; mucosa inflammation; antineoplastic agents, phytogenic; dexamethasone; docetaxel; drug hypersensitivity; urologic neoplasms; drug response; remission induction; taxoids; carcinoma, transitional cell; alopecia; transitional cell carcinoma; intravenous drug administration; diphenhydramine; humans; human; male; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 15 |
| Issue: | 5 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1997-05-01 |
| Start Page: | 1853 |
| End Page: | 1857 |
| Language: | English |
| PUBMED: | 9164195 |
| PROVIDER: | scopus |
| DOI: | 10.1200/JCO.1997.15.5.1853 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 17 March 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work